Ocugen

This preclinical pharmacological study performed by Neena Haider, Ph.D.'s team evaluated the effect of NR2E3 gene therapy in the rd7 animal model of retinal degeneration at various doses in early and intermediate stages of the disease. NR2E3 gene therapy improved photoreceptor survival, retinal function, and retinal structure at all dose levels. This effect was sustained for 6 months (study duration) after a single subretinal injection in both early and intermediate stage of the disease. This study highlights the therapeutic potential of NR2E3 modifier gene therapy for patients with retinitis pigmentosa (RP). https://lnkd.in/e7HbRter. #RP #GeneTherapy  

Ocugen Chief Medical Officer, Dr. Huma Qamar, addressed the significance of treating rare diseases--and meeting regional needs across the globe--during the most recent ADFO Summit. Ocugen is committed to shifting the treatment paradigm for inherited retinal diseases and grateful for the opportunity to share our clinical progress among new and meaningful audiences. #IRD #modifiergenetherapy #courageousinnovation

Ocugen has been included in the Lehigh University Pennsylvania 100 Index—a newly established stock index that aims to showcase the economic growth of Pennsylvania. The index comprises the 100 largest companies domiciled in Pennsylvania using a Free-Float Market-Capitalization methodology. We are honored to be recognized as one of the most prominent companies driving the progress of the state’s economic growth.   Visit https://lnkd.in/eAkhsTHG to learn more about the index, its methodology, and the companies that comprise it. Additionally, you can follow the project on LinkedIn at https://lnkd.in/eDXEcSZP.

Hear from a patient with retinitis pigmentosa (RP) who participated in the OCU400 Phase 1/2 clinical trial. RP is a group of rare, genetic disorders that involve a breakdown and loss of cells in the retina, leading to vision loss and blindness. Currently, RP is associated with mutations in more than 100 genes affecting nearly 300,000 people in the U.S. and Europe combined. There are no approved treatment options that slow or stop the progression of multiple forms of RP. OCU400 has the potential to bring hope to people living with RP. If you are interested in learning more about the OCU400 Phase 3 liMeliGhT clinical trial, contact: [email protected] #RetinitisPigmentosa #IRD #genetherapy

Your vision matters! Join us in observing Eye Injury Prevention Month by wearing protective eyewear and prioritizing eye safety. #EyeInjuryPreventionMonth

Thanks @CGTLive for sharing the exciting news of the first patient dosed in our OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa. #RP #IRD

Reflecting on the spirit of Independence Day this Fourth of July. Wishing everyone a safe and celebratory day! #FourthofJuly #IndependenceDay

Marking the 40th year of Deafblind Awareness Week, let's celebrate the strength, resilience, and incredible abilities of the Deafblind community. Together, we can foster an environment where everyone can thrive. #DeafblindAwarenessWeek

During the 2nd Retinal Imaging Biomarkers & Endpoints Summit, Ocugen’s CSO and Head of Research & Development, Arun Upadhyay, will moderate a roundtable discussion regarding the latest trends in retinal imaging for retinal disorders including: IRDs, geographic atrophy, wet AMD, DME and glaucoma. Following the roundtable discussion, he will present back to the entire delegation and lead a wider audience debate. To register for this event, go to https://lnkd.in/dWT4p9VB.

Submitting your proxy vote is easy! Be sure to vote and then join us for the 2024 Annual Meeting of Shareholders to be held on June 28, 2024.